Century Therapeutics Inc (IPSC)

$3.25

-0.05

(-1.52%)

Market is closed - opens 7 PM, 30 May 2024

Insights on Century Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 99.0K → 855.0K (in $), with an average increase of 48.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -39.39M → -28.06M (in $), with an average increase of 40.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 66.0% return, outperforming this stock by 59.4%

Performance

  • $3.10
    $3.39
    $3.25
    downward going graph

    4.62%

    Downside

    Day's Volatility :8.55%

    Upside

    4.13%

    downward going graph
  • $1.28
    $5.51
    $3.25
    downward going graph

    60.62%

    Downside

    52 Weeks Volatility :76.77%

    Upside

    41.02%

    downward going graph

Returns

PeriodCentury Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-11.44%
-2.3%
0.0%
6 Months
137.23%
7.8%
0.0%
1 Year
6.56%
11.7%
0.0%
3 Years
-88.23%
14.5%
-22.0%

Highlights

Market Capitalization
274.5M
Book Value
$2.75
Earnings Per Share (EPS)
-2.43
Wall Street Target Price
14.17
Profit Margin
0.0%
Operating Margin TTM
-3661.87%
Return On Assets TTM
-19.33%
Return On Equity TTM
-58.66%
Revenue TTM
1.4M
Revenue Per Share TTM
0.02
Quarterly Revenue Growth YOY
-50.3%
Gross Profit TTM
5.2M
EBITDA
-111.0M
Diluted Eps TTM
-2.43
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.88
EPS Estimate Next Year
-1.78
EPS Estimate Current Quarter
-0.5
EPS Estimate Next Quarter
-0.49

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Century Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 336.0%

Current $3.25
Target $14.17

Technicals Summary

Sell

Neutral

Buy

Century Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Century Therapeutics Inc
Century Therapeutics Inc
11.68%
137.23%
6.56%
-88.23%
-88.23%
Moderna, Inc.
Moderna, Inc.
34.09%
90.37%
17.56%
-19.9%
588.32%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
8.51%
17.32%
32.65%
92.06%
213.84%
Novo Nordisk A/s
Novo Nordisk A/s
3.41%
30.28%
66.05%
235.09%
462.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
12.3%
24.33%
35.61%
110.39%
159.09%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Century Therapeutics Inc
Century Therapeutics Inc
45.5
NA
NA
-1.88
-0.59
-0.19
NA
2.75
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.07
29.07
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
47.21
47.21
2.36
3.51
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.67
29.67
0.53
17.14
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Century Therapeutics Inc
Century Therapeutics Inc
Buy
$274.5M
-88.23%
45.5
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$56.7B
588.32%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$107.2B
213.84%
29.07
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$597.3B
462.44%
47.21
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.3B
159.09%
29.67
39.46%

Institutional Holdings

  • FMR Inc

    4.36%
  • Casdin Capital, LLC

    3.87%
  • Boxer Capital LLC

    2.11%
  • BlackRock Inc

    1.83%
  • Dafna Capital Management LLC

    1.58%
  • Avidity Partners Management LP

    1.47%

Company Information

Century Therapeutics, Inc. specializes in adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first generation cell therapies as well as provides testing and research services.

Organization
Century Therapeutics Inc
Employees
152
CEO
Dr. Adrienne Farid Ph.D.
Industry
Non-Energy Minerals

FAQs